Medical*Online-E FAQ

Detailed Description of Translation Function
Overview
 Background
Dissemination of Japanese research has always suffered at the hands of the language barrier. In the field ofmedicine, improving the availability of Japan’s medical articles has been a challenge for a long time toMeteo Inc., Japan’s leading provider of medical database. In order to address this issue, in 2014,mechanical translation function was built into Medical*Online-E to enable medical professionals aroundthe globe to discover unique resources untapped outside Japan.
 Features
 On-board medical dictionary customized according to professional needs to produce high-qualitytranslation
 Easy operation to generate translation by simply copying the sentences and pasting them into the textbox
 Multiple translation helps you read Japanese article in English, Chinese and Korean

1/6Medical*Online-E FAQ

Understanding Article’s Structure - 1
 Article consists of:
Header

Pagination
Title
Authors
Abstract
Keywords

Body
Footnote
Footer2/6

Medical*Online-E FAQ

Understanding Article’s Structure - 2
 Downloaded PDF consists of:Image
Not Translatable

Double-column Format

Text
Translatable3/6

Medical*Online-E FAQ

Understanding Article’s Structure - 3
 Japanese Sentences
Unlike western languages, there is no inter-word space in Japanese sentences. On the other hand, every
paragraph starts with “ ” (space) and every sentence ends with “ . ” (period) or “ 。” (maru). These uniquecharacteristics make it difficult for non-Japanese people to distinguish translation unit.
Paragraph starts with space.
Sentence ends with period.
Sentence ends with period.
Sentence ends with period.
Sentence ends with period.
Sentence ends with period..
Paragraph starts with space.

4/6

Medical*Online-E FAQTranslation Step - 1
 Open PDF and select targeted portion(s)

31
2

5/6

Medical*Online-E FAQTranslation Step - 2
 Copy portion(s) and paste them into text box in Translation tool

Paste 1
Paste 2
Paste 3
Translate

GeneratedTranslation

高齢化が進む今日，成人が発症する認知症の代表的な疾患であるアルツハイマー型認知症（Alzheimer’s disease：AD）の罹患者数増大は深刻な社会問題になりつつある．その生化学的メカニ
ズムは依然として未知な点が多いものの，タンパク質のミスフォールディング（折りたたみ異常）が関わる疾患であることは判明しており，AD 罹患者の脳には異常に折りたたまれたアミロイドβタンパク質（Aβ）の蓄積がみられる［1］． 近年，生体イメージング技術の進歩によって，生体の形態および機能に関する，さまざまな可視化技術が発達してきた．特に PET（positron emission tomography）やSPECT（single photon emission computed tomography）のような核医学イメージングによる生体機能の可視化は，脳血流，悪性腫瘍の診断などに応用され，その有用性は年々高まりつつある．一方
で，AD 診断のための PET 用標識化合物の開発も進み， PET アミロイドイメージングが，既存の診断方法では困難な AD の早期診断に有効である事例が報告されている［2－13］．PET アミロイドイメージ
ングは，大脳皮質に蓄積する Aβを，アミロイドのβシート構造に親和性の高い低分子化合物を短半減期の放射性同位元素で標識した化合物を用いて画像化する．
PET アミロイドイメージングの直面する問題のひとつに，部分容積効果（partial volume effects：PVE）が挙げられる． PVE は，［18F］FDG（廿 uoro．deoxyglucose）PET 検査のように，陰性所見を抽出すべき検査では糖代謝低下の過大評価をもたらし，偽陽性を増大させるだけなのに対し，アミロイドPET 検査のように，異常集積増加を抽出すべき検査においては，PVE は不利に働き，偽陰性ンして得られた GM および WM 確率マップを用いて，SPECT のための PVC 方法を提案した［15］．本研究では，Matsuda らのコンセプトを踏襲して，CTに基づく PETの PVCを実行する．PVC
後，thatPET
AD 診断のための画像を作成する．
Alzheimer
disease(Alzheimer's disease:is 画像からrepresentative
disease of SUVR
dementia
to develop in
処理フローを図1 に示す．
adultstoday thataging advances to The number of the affected subjects increase of AD) is
becoming the serious social problem. Although there are many still unknown points, as for thebiochemical mechanism, it becomes clear to be the disease that misfolding (folding abnormality)of the protein is associated with, and accumulation of amyloid β protein (Aβ) which wasabnormally folded is found in the brain of AD affected subjects [1].
In late years, by the progress of the living body imaging technology, a various visualization
technology about organic form and the function developed. PET (positron emission tomography)
in particular and SPECT (single photon emission
The visualization of the biological function by the radionuclide imaging such as computedtomography) is applied to cerebral blood flow, the diagnosis of the malignant tumor, and theutility is increasing year by year. Whereas [2-13] reported the example that is effective for early
diagnosis of AD which advances to the development of the labeled compound for the PET for AD
6 / 6 method a PET amyloid imaging. The PET
diagnoses, and is difficult by the existing diagnostic
amyloid imaging images a high small molecule compound of the affinity using a radioisotope forthe short half life-labeled compound in beta sheet structure of the amyloid in Aβ accumulating
to the brain cortex.
One of the problems that the PET amyloid imaging faces includes partial volume effect (partialvolume effects: PVE). In the testing that should extract abnormality accumulation increase likeamyloid PET testing, PVE worked disadvantageously whereas PVE resulted in the overestimate